consumer_protection · agriculture · food_and_nutrition · HHS-FDA
Studies Addressing Rare Neurodegenerative Diseases including ALS
Food and Drug Administration · FOR-FD-25-006
Expected Awards
10
Deadline
TBD
GRANTQUICK SUMMARYPlain-English Overview
Studies Addressing Rare Neurodegenerative Diseases including ALS. Food and Drug Administration. The purpose of this funding opportunity announcement (FOA) is to support studies that advance medical product development of interventions intended to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in adults and children. Through the support of these... ~10 awards expected.
Who Should Apply
Unrestricted (any eligible entity), State governments, Independent school districts, Private universities/colleges, City/township governments (+10 more)
Who Should NOT Apply
Few restrictions — most eligible entities can apply
Key Requirements (Plain English)
- •See full opportunity listing for requirements
💡 GrantQuick Tip
Focus your proposal on clear outcomes, alignment with agency priorities, and demonstrate organizational capacity.
Competitiveness: High — limited number of awards
What This Grant Funds
The purpose of this funding opportunity announcement (FOA) is to support studies that advance medical product development of interventions intended to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in adults and children. Through the support of these studies, FDA expects to address critical knowledge gaps, exert a significant impact on rare neurodegenerative diseases, and to inform current or future product development.
Who Can Apply
Eligible Applicant Types
Funding Details
- Expected Number of Awards
- 10
- Cost Sharing Required?
- No
- Funding Instrument
- grant
Key Dates
Agency Contact
Terrin Brown Grantor 2404027610
terrin.brown@fda.hhs.govReady to apply?
View the full NOFO and submit your application on Grants.gov